From Immunomonitoring to Immune Intervention by Antoine Toubert & Hermann Einsele
EDITORIAL
published: 06 January 2015
doi: 10.3389/fimmu.2014.00669
From immunomonitoring to immune intervention
AntoineToubert 1 and Hermann Einsele2*
1 Immunology-Histocompatibility, Laboratoire d’Immunologie et d’Histocompatibilité, Laboratoire Jean Dausset, INSERM, Assistance Publique Hôpitaux de Paris,
Université Paris Diderot, Paris, France
2 Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany
*Correspondence: einsele_h@ukw.de
Edited and reviewed by:
Effie Wang Petersdorf, University of Washington School of Medicine, USA
Keywords: HSCT, immune reconstitution, thymic function, cell therapy, Haplo-SCT
Host immune status is a key issue in allogeneic hematopoi-
etic stem cell transplantation (allo-HSCT). In the long-term
follow-up of these patients, severe post-transplant infections,
relapse or secondary malignancies may be directly related to pro-
longed immune defects, especially in the context of innovative
stem cell sources such as umbilical cord blood transplantation
(CBT) (1) or transplants from HLA haplo-identical family donors
(Haplo-HSCT) (2, 3).
This Frontiers Research Topic provides insights into mecha-
nisms of immune reconstitution in an allogeneic environment,
in order to improve monitoring and therapeutic intervention in
allo-HSCT patients.
Forcina et al. (4) critically review T and NK biomarkers, their
threshold and clinical relevance. Many factors from the host,
transplant conditioning, stem cell source, and genetic disparity
may impact immune recovery. Few biomarkers have reached a
clinical consensus: a rapid and potent CD4 T-cell recovery is
associated with a favorable clinical outcome, CMV-specific CD8
T-cell counts measured by tetramers can predict a lower inci-
dence of CMV disease. Other phenotypic or molecular markers,
still based on small-sized studies, will need further validation
in large scale-multicentric cohorts. This is the case of molecu-
lar markers of lymphocyte generation, such as T-cells evaluated
by the quantification of T-cell rearrangement excision circles
(TREC) as a surrogate marker of thymic activity. Clave et al. (3)
indicate an impact of thymic function recovery on relapse fol-
lowing CBT as well as Haplo-HSCT in children treated for an
hematological malignancy. In order to reach the routine med-
ical practice, immunomonitoring tests need also to be simple and
fast. This practical issue is well taken into account by Fuji et al.
(5) reviewing T-cell monitoring of viral and fungal infections.
CMV is still the most intensively studied virus in immunocom-
promised hosts. CMV shapes T and NK cell responses in many
ways and may escape immune response. Among still unanswered
questions, is the role of viral-specific (CMV and EBV) T-cell
cross-reactivity against allogeneic targets in graft-versus-host and
graft-versus-leukemia (6).
Experimental models have proved their importance in allo-
HSCT, especially deciphering mechanisms of allogeneicity in
graft-versus-host disease (GVHD). Among rodents, rat mod-
els are relevant especially in some autoimmune conditions and
solid organ transplantation, sometimes closer to the human dis-
ease than the “gold standard” murine models. Zinöcker et al.
(7) emphasize the interest of rat model in experimental GVHD,
especially the rat skin explant assay as a tool for functional
evaluation of GVHD. Experimental models are also required to
provide the basis and for preclinical evaluation of immune-based
therapies.
This Frontiers Research Topic also reviews in some strategies
already proposed in the clinics. Adoptive T-cell therapies have
been conducted successfully by several groups to control life-
threatening viral (EBV, CMV) reactivations. This leads to “off the
shelf” strategies based on third party HLA-typed T-cell donors
registries, which may have a major impact in transplant recipi-
ents (8). The development of therapeutic antibodies in cancer is
one of the most active fields in clinical immunology. Many strate-
gies are underway to improve their action, especially through their
antibody-dependent cellular toxicity mediated by natural killer
(NK) cells (9). One approach especially relevant in allo-HSCT
would be to take advantage of the killer-immunoglobulin-like
receptor (KIR) ligand incompatibility in addition to ADCC to
boost NK functions.
The impact of these different concepts, from basic knowl-
edge to translational medicine, is integrated in state-of-the art
reviews of two main “success stories” in allo-HSCT: CBT (1) and
Haplo-HSCT (2).
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